Recently, the FDA has approved tazemetostat, an EZH2 methyltransferase, for the treatment of adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for radical resection [50]. Here, EZH2 is linked to epithelioid sarcoma.